tradingkey.logo
搜尋

Exact Sciences Corp

EXAS
添加自選
104.910USD
0.0000.00%
收盤 06/29, 16:00美東報價延遲15分鐘
20.03B總市值
虧損本益比TTM

關於 Exact Sciences Corp 公司

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp簡介

公司代碼EXAS
公司名稱Exact Sciences Corp
上市日期Jan 30, 2001
CEOConroy (Kevin T)
員工數量6900
證券類型Ordinary Share
年結日Jan 30
公司地址5505 Endeavor Lane
城市MADISON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編53719
電話16082845700
網址https://www.exactsciences.com/
公司代碼EXAS
上市日期Jan 30, 2001
CEOConroy (Kevin T)

Exact Sciences Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

常見問題

Exact Sciences Corp的前五大股東是誰?

Exact Sciences Corp的前五大股東如下:Mr. Kevin T. Conroy

有多少機構持有Exact Sciences Corp(EXAS)的股份?

截至2026Q1,共有1452家機構持有Exact Sciences Corp的股份,合計持有的股份價值約為147.12M,占公司總股份的77.07% 。與2025Q4相比,機構持股有所增加,增幅為-48700001.00。

哪個業務部門對Exact Sciences Corp的收入貢獻最大?

在2026Q1,Commercial業務部門對Exact Sciences Corp的收入貢獻最大,創收1.52B,占總收入的46.79% 。
KeyAI